Search

Background and Aims: Small-bowel (SB) capsule endoscopy (CE) is a first-line procedure for exploring the SB. Endoscopic GI PlacemenT (EGIPT) of SB CE is sometimes necessary. Although experience with EGIPT is considerable in pediatric populations, we aimed to describe the safety, efficacy, and outcomes of EGIPT of SB CE in adult patients., Methods: The international CApsule endoscopy REsearch (iCARE) group set up a retrospective multicenter study. Patients over age 18 years who underwent EGIPT of SB CE before May 2022 were included. Data were collected from medical records and capsule recordings. The primary endpoint was the technical success rate of the EGIPT procedures., Results: Of 39,565 patients from 29 centers, 630 (1.6%) were included (mean age, 62.5 years; 55.9% women). The technical success of EGIPT was achieved in 610 procedures (96.8%). Anesthesia (moderate to deep sedation or general anesthesia) and centers with intermediate or high procedure loads were independent factors of technical success. Severe adverse events occurred in 3 patients (.5%). When technically successful, EGIPT was associated with a high SB CE completion rate (84.4%) and with a substantial diagnostic yield (61.1%). The completion rate was significantly higher when the capsule was delivered in the SB compared with when it was delivered in the stomach., Conclusions: EGIPT of SB CE is highly feasible and safe, with a high completion rate and diagnostic yield. When indicated, it should be performed with patients under anesthesia, and the capsule should be delivered in the duodenum rather than the stomach for better SB examination outcomes., Competing Interests: Disclosure The following authors disclosed financial relationships: S. Ouazana: Speaker for Medtronic. P. Baltes: Speaker for Medtronic; research support from AnX Robotics. E. Toth: Consultant for AnX Robotics, Jinshan, Medtronic, and Norgine; speaker for Jinshan, Medtronic, and Tillotts Pharma; research support from AnX Robotics, Jinshan, and Norgine. H. Beaumont: Speaker for Medtronic. C. Spada: Advisor for AnX Robotics and Medtronic; speaker for AnX Robotics, Boston Scientific, and Olympus; research support from Pentax. A. Mussetto: Consultant for Boston Europe and Olympus Italia. R. Sidhu: Consultant for AnXRobotics. D. McNamara: Speaker for Medtronic and Takeda. B. González-Suárez: Research support from Medtronic; speaker for Norgine and Olympus. C. Carretero: Advisor for Medtronic. E. Despott: Research support from Fujifilm, Aquilant Endoscopy, Pentax Medical, Olympus, Boston Scientific, GI Supply, Cook Medical, Diagmed Healthcare, Norgine, Takeda, Abbvie, Cantel Medical, Ardmore Medical, Apollo Endosurgery, Erbe, APR Medical, AnX Robotics, and Medtronic; consultant for Fujifilm, Norgine, and Ambu; speaker for Fujifilm, Aquilant Endoscopy, Olympus, Boston Scientific, GI Supply, Ambu, and Aquilant Endoscopy. E. Rondonotti: Speaker and consultant for Fujifilm; consultant for Medtronic. J. Kirchgesner: Consultant for Janssen, Celltrion, Roche, Pfizer, and Gilead; speaker for Janssen and Lilly. X. Dray: Speaker for Alfasigma, Bouchara Recordati, Fujifilm, Medtronic, Norgine, and Sandoz; co-founder of and shareholder in Augmented Endoscopy; consultant for Norgine and Provepharma. All other authors disclosed no financial relationships., (Copyright © 2024 American Society for Gastrointestinal Endoscopy. Published by Elsevier Inc. All rights reserved.)